Catalog No.
RHC35401
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000
Target
CYPIIIA3, Cytochrome P450 3A4, 1,4-cineole 2-exo-monooxygenase, CYP3A4, Cytochrome P450 3A3, Cytochrome P450 NF-25, Cytochrome P450-PCN1, CYPIIIA4, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Nifedipine oxidase, Quinine 3-monooxygenase, CYP3A3, Cholesterol 25-hydroxylase, Cytochrome P450 HLp, Albendazole sulfoxidase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08684
Applications
IHC, IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1L77
Construction and evaluation of glucocorticoid dose prediction model based on genetic and clinical characteristics of patients with systemic lupus erythematosus., PMID:40186486
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease., PMID:39707077
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model., PMID:39285155
Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis., PMID:38993026
Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis., PMID:38984761
In Vitro Metabolism and Transport Characteristics of Zastaprazan., PMID:38931920
Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies., PMID:38889292
An in silico investigation of the toxicological effects and biological activities of 3-phenoxybenzoic acid and its metabolite products., PMID:38833509
Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience., PMID:38363388
Immune outcomes of lung transplant recipients with different cytochrome P450 3A5 phenotypes after discontinuation of voriconazole antifungal prophylaxis., PMID:38289893
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling., PMID:38050329
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab., PMID:38044486
Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach., PMID:37964462
Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study., PMID:37928419
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review., PMID:37925645
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite., PMID:37872122
Possible New Histological Prognostic Index for Large B-Cell Lymphoma., PMID:37834968
Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin., PMID:37632598
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial., PMID:37532416
The Influence of Lipid Microdomain Heterogeneity on Protein-Protein Interactions: Proteomic Analysis of Co-Immunoprecipitated Binding Partners of P450 1A2 and P450 3A in Rat Liver Microsomes., PMID:37349115
Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs., PMID:37144920
Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study., PMID:36467034
Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer., PMID:36377026
[Acute Myeloid Leukemia - Update 2022]., PMID:36030783
Dietary aflatoxin B1 caused the growth inhibition, and activated oxidative stress and endoplasmic reticulum stress pathway, inducing apoptosis and inflammation in the liver of northern snakehead (Channa argus)., PMID:35964742
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy., PMID:35895276
Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation., PMID:35833145
Development of a UPLC-MRM-based targeted proteomic method to profile subcellular organelle marker proteins from human liver tissues., PMID:35768540
Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation., PMID:35466485
Mycotoxins binder supplementation alleviates aflatoxin B1 toxic effects on the immune response and intestinal barrier function in broilers., PMID:35121530
Interfering with cholesterol metabolism impairs tick embryo development and turns eggs susceptible to bacterial colonization., PMID:34325088
Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype., PMID:34241984
Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism., PMID:34153143
Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients., PMID:34129685
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications., PMID:34044300
Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation., PMID:33971831
The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice., PMID:33627744
Case Report: Signal Transducer and Activator of Transcription 3 Gain-of-Function and Spectrin Deficiency: A Life-Threatening Case of Severe Hemolytic Anemia., PMID:33519826
Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments., PMID:33368439
Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases., PMID:33331142
Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies., PMID:33287305
High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors., PMID:33278239
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials., PMID:33205435
Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo., PMID:33183197
Regioselective Hydroxylation of Phloretin, a Bioactive Compound from Apples, by Human Cytochrome P450 Enzymes., PMID:33105851
Gender differences in plasma pharmacokinetics and hepatic metabolism of geissoschizine methyl ether from Uncaria hook in rats., PMID:32898626
Midazolam oxidation in cattle liver microsomes: The role of cytochrome P450 3A., PMID:32893906
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy., PMID:32717568
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations., PMID:32641296
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19., PMID:32587121
For research use only. Not for human or drug use.
